1. Home
  2. RILY vs LPTX Comparison

RILY vs LPTX Comparison

Compare RILY & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RILY
  • LPTX
  • Stock Information
  • Founded
  • RILY 1973
  • LPTX 2011
  • Country
  • RILY United States
  • LPTX United States
  • Employees
  • RILY N/A
  • LPTX N/A
  • Industry
  • RILY Investment Managers
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • RILY Finance
  • LPTX Health Care
  • Exchange
  • RILY Nasdaq
  • LPTX Nasdaq
  • Market Cap
  • RILY 88.4M
  • LPTX 119.6M
  • IPO Year
  • RILY 2007
  • LPTX N/A
  • Fundamental
  • Price
  • RILY $2.82
  • LPTX $0.36
  • Analyst Decision
  • RILY
  • LPTX Buy
  • Analyst Count
  • RILY 0
  • LPTX 2
  • Target Price
  • RILY N/A
  • LPTX $8.00
  • AVG Volume (30 Days)
  • RILY 654.2K
  • LPTX 381.5K
  • Earning Date
  • RILY 05-20-2025
  • LPTX 05-20-2025
  • Dividend Yield
  • RILY 17.73%
  • LPTX N/A
  • EPS Growth
  • RILY N/A
  • LPTX N/A
  • EPS
  • RILY N/A
  • LPTX N/A
  • Revenue
  • RILY $854,383,000.00
  • LPTX N/A
  • Revenue This Year
  • RILY N/A
  • LPTX N/A
  • Revenue Next Year
  • RILY N/A
  • LPTX N/A
  • P/E Ratio
  • RILY N/A
  • LPTX N/A
  • Revenue Growth
  • RILY N/A
  • LPTX N/A
  • 52 Week Low
  • RILY $2.67
  • LPTX $0.22
  • 52 Week High
  • RILY $37.08
  • LPTX $4.79
  • Technical
  • Relative Strength Index (RSI)
  • RILY 36.58
  • LPTX 45.04
  • Support Level
  • RILY $2.80
  • LPTX $0.32
  • Resistance Level
  • RILY $3.10
  • LPTX $0.38
  • Average True Range (ATR)
  • RILY 0.19
  • LPTX 0.03
  • MACD
  • RILY 0.03
  • LPTX 0.00
  • Stochastic Oscillator
  • RILY 11.30
  • LPTX 37.36

About RILY B. Riley Financial Inc.

B. Riley Financial Inc is a diversified financial services company. The company through its subsidiaries offers investment banking and financial services to corporate, institutional, and high-net-worth clients and also asset disposition, valuation and appraisal, and capital advisory services to retail, wholesale, institutional, lenders, capital providers, private equity investors, and professional services firms in United States, Canada, and Europe. It also provides internet access and subscription services. The reportable operating segments of the company include Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications segment, and Consumer products segment.

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

Share on Social Networks: